Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 7751 - 7800ASH 2019: New Genomic Mutational and Expressional Data in AML, MDS
Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene-expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The research was presented by Iacobucci et al during the 2019 American Society...
ASH 2019: Oral Azacitidine Improves Survival in Older Patients With AML in First Remission
Treatment with an investigational oral form of azacitidine, CC-486, improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study...
Hematologist/Oncologist Augustine L. Perrotta, DO, Dies at 80
On November 24, hematologist/oncologist Augustine L. Perrotta, DO, died, days before his 81st birthday. Ironically, Dr. Perrotta died of renal cell carcinoma, presenting with metastasis to the spine, a topic about which he had written and lectured extensively. Clinical Professor of Medicine at...
Scott A. Gerber, PhD, Named Inaugural Kenneth E. and Carol L. Weg Distinguished Professor at Dartmouth
Scott A. Gerber, PhD, has been named the Kenneth E. and Carol L. Weg Distinguished Professor at Geisel School of Medicine at Dartmouth College. Dr. Gerber is the first to hold this newly established professorship. Dr. Gerber is Professor of Molecular and Systems Biology and of Biochemistry and...
Having Cancer Should Not Make You Homeless
In the spring of 2005, I was launching a new career as a sales consultant for a startup graphics company and wanted to cross off a few essential things on my to-do list, including getting my annual mammogram and physical, before I started my new job. Although I was surprised when I got a call from ...
Study Investigates Quality-of-Life Scores as Prognostic Factors in Patients With Cancer
Patients with cancer who report on their own quality of life can provide information important in predicting the outcome of their disease, according to researchers from the European Organisation for Research and Treatment of Cancer (EORTC). Until recently, reports from clinicians on issues such as...
Global Survey Shows Misperceptions About Lung Cancer Among the General Public
Only one in five people (22%) disagrees with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices and behaviors,” according to a global, omnibus survey conducted by Ipsos MORI and sponsored by the Lung Ambition Alliance. The results were...
ACCC Project Focuses on Multidisciplinary Care of Cutaneous Squamous Cell Carcinoma
Due to the rarity of advanced cutaneous squamous cell carcinoma, staying current with the latest information on diagnosing, treating, and supporting patients with this diagnosis can be challenging for clinicians who do not often encounter it in practice. To support the multidisciplinary cancer team ...
Alan Hutson, PhD, MA, to Serve on St. Jude Children’s Research Hospital Data Safety Monitoring Board
Alan Hutson, PhD, MA, now holds a 5-year term as a biostatistics expert for the data safety monitoring board at St. Jude Children’s Research Hospital. Dr. Hutson is Chair and Professor of Oncology in the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. At ...
Partners HealthCare to Become Mass General Brigham: 5-Year Strategic Plan
Partners HealthCare President and Chief Executive Officer, Anne Klibanski, MD, unveiled a 5-year strategic plan and announced plans for rebranding its health-care system. Partners HealthCare, which serves more than 1.5 million patients and receives nearly $2 billion in research funding annually,...
NCCN Updates Genetic Screening Guidelines
The National Comprehensive Cancer Network® (NCCN®) recently announced publication of the newest genetic risk assessment recommendations for breast, ovarian, and pancreatic cancers. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment:...
Studies Show the U.S. Health-Care System Hampered by Waste and Trailing Other High-Income Countries
Recent studies show that at least one-quarter of our nation’s health-care expenditures are being consumed by waste, fraud, and abuse. Moreover, since 2004, annual reports from the Commonwealth Fund have consistently rated the performance of our health-care system last among high-income countries,...
Collaborative Trial to Evaluate Imaging Methods for Women With Dense Breasts
In a new effort to improve early breast cancer detection and reduce false-positive exams in women with dense breasts, the American College of Radiology (ACR), the Breast Cancer Research Foundation (BCRF), and GE Healthcare are partnering to support the Contrast-Enhanced Mammography Imaging...
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Earlier this month, the American Society of Hematology (ASH) published new state-of-the-art guidelines on the treatment of immune thrombocytopenia. The guidelines were published in the journal Blood Advances.1 The 2019 ASH Clinical Practice Guidelines on Immune Thrombocytopenia, developed in...
Working to Improve Survival Rates in Pancreatic Cancer
Although pancreatic cancer survival rates have slowly improved over the past few decades for all stages of pancreatic cancer combined, the 1-year rate is 20%, and the 5-year rate is about 9%. There is no single diagnostic test to detect pancreatic cancer, and less than 20% of tumors are confined to ...
Antibiotics and Immune Checkpoint Blockade in Patients With Cancer: First Do No Harm
Despite the unprecedented improvement in clinical outcomes with the advent of immune checkpoint blockade for cancer,1,2 robust biomarkers for therapeutic success as well as novel strategies to increase their efficacy are urgently needed. In addition to exploring novel immune checkpoints and other...
Carolyn C. Meltzer, MD, Joins Board of Directors for RSNA
Carolyn C. Meltzer, MD, neuroradiologist, nuclear physician, and leader in organized radiology, joined the Radiological Society of North America (RSNA) Board of Directors earlier this month at the Society’s annual meeting in Chicago. She will serve as the board liaison for science. “I am delighted ...
An Early Interest in Biology and People Led to a Career in Oncology for Nina Shah, MD
Multiple myeloma expert Nina Shah, MD, was born and reared in the Northeast. During grade school, she developed a passion for science that would lead to an early decision to pursue a career in medicine. “My ninth-grade biology class really got me interested in human biology, and that’s when I...
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
On December 4, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with chemotherapy (nab-paclitaxel and carboplatin) for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic...
First-Line Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma
On April 19, 2019, pembrolizumab was approved for use in combination with the small-molecule tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma.1,2 Supporting Efficacy Data Approval was based on findings in the open-label phase III...
Mary Jo Turk, PhD, Named O. Ross McIntyre, MD, Professor at Dartmouth College
Mary Jo Turk, PhD, has been named the O. Ross McIntyre, MD, Professor at the Geisel School of Medicine at Dartmouth College. Professor of Microbiology and Immunology and Co-Director of the Immunology and Cancer Immunotherapy Program at Dartmouth’s Norris Cotton Cancer Center, Dr. Turk joined the...
Impact of Malnutrition and Physical Inactivity on Cancer Care
A number of patients involved in clinical trials for drugs being developed to treat cancer may be malnourished and sedentary, a factor that may result in inaccurate results for the trials, according to a new study from researchers at Fox Chase Cancer Center published in The Oncologist.1 “We found...
The Light at the End of the Tunnel in Urothelial Cancer Is Not a Train: Enfortumab Vedotin and Other Developments
There is an urgent need to develop new drugs for the treatment of urothelial cancer. Chemotherapy was the only approved treatment in advanced disease for 40 years, which was associated with response rates of between 30% and 50% in the front-line setting.1-3 However, durable remissions were...
David P. Steensma, MD, on Myeloid Neoplasms: Results From a First-in-Human Trial of a Splicing Modulator
David P. Steensma, MD, of Dana-Farber Cancer Institute, discusses early study findings on H3B-8800, which decreased the need for red blood cell or platelet transfusion in 14% of patients. This splicing modulator, used in the trial to treat patients with hematologic malignancies, also showed safety, ...
Mary-Claire King, PhD, Joins New York Genome Center as Senior Associate Core Member
The New York Genome Center announced recently that Mary-Claire King, PhD, has joined its faculty on a consulting basis as Senior Associate Core Member. Dr. King will provide scientific leadership in the genetics of neuropsychiatric disease. Dr. King is the American Cancer Society Professor in the...
IASLC Appoints Chandra P. Belani, MD, as New Chief Science Officer
The International Association for the Study of Lung Cancer (IASLC) has named Chandra P. Belani, MD, as its new Chief Science Officer. In this position, Dr. Belani will direct, guide, and support the IASLC scientific strategy, including, but not limited to, scientific research projects,...
Make a Holiday Gift to Conquer Cancer,® the ASCO Foundation
Help fund breakthrough cancer research on behalf of someone you love this holiday season. Make a gift in honor or in memory of a loved one, and then send an e-card or mailed notification of your tribute. For many families, this time of year is marked by worry or grief rather than joy. With your...
First Department of Veterans Affairs System Achieves QOPI® Certification
The Quality Oncology Practice Initiative (QOPI®) Certification Program continues to expand its reach, certifying the first system within the U.S. Department of Veterans Affairs (VA)—the Salisbury VA Health Care System—on October 9. The system, which includes a main facility—the W. G. (Bill) Hefner...
Your Stories Podcast Returns in 2020 With New Episodes
A new season of Your Stories, the popular podcast series from Conquer Cancer®, the ASCO Foundation, will premiere in 2020. New episodes will be released bimonthly and will feature candid conversations among doctors, patients, caregivers, and research pioneers on their experiences conquering ...
New Policy Brief Explains How Co-pay Accumulators, Maximizers Increase Cost of Cancer Care for Patients
Health insurers, employers, and pharmacy benefit managers (PBMs) have shifted a growing share of the costs for specialty prescription medicines to their patients and beneficiaries. Since insurer cost-sharing requirements for prescription medications can be uniquely burdensome compared to other...
For Your Patients: What Are Tumor Marker Tests for Cancer? Eight Things You Need to Know
Cancer.Net provides timely, comprehensive, oncologist-approved information for patients from ASCO with support from Conquer Cancer®, the ASCO Foundation. Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for them to help patients and families make ...
Conquer Cancer®, the ASCO Foundation, Hosts Scientific and Career Development Retreat
Conquer Cancer®, the ASCO Foundation, hosted its fifth annual Scientific and Career Development Retreat on October 29 and 30, 2019, at ASCO Headquarters in Alexandria, Virginia. The event encourages networking and scientific collaboration among Young Investigator Award (YIA) and Career Development...
JOP Editor-in-Chief Brings Value-Based Care to Journal’s Forefront
In January 2019, Linda D. Bosserman, MD, FACP, FASCO, began her tenure as Editor-in-Chief of the Journal of Oncology Practice (JOP). An Assistant Clinical Professor and staff physician at City of Hope, Dr. Bosserman has served on the ASCO Board of Directors and was a founding member of the TAPUR...
Erlotinib Plus Ramucirumab: Ready for Prime Time?
The treatment of epidermal growth factor receptor (EGFR)-positive lung cancer changed dramatically after the results of the FLAURA trial showed improved progression-free survival with the third-generation EGFR tyrosine kinase inhibitor osimertinib as first-line therapy compared with...
Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the vascular endothelial growth factor inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unresectable hepatocellular carcinoma compared with sorafenib, according...
ASH 2019: Pilot Study of Next-Generation Sequencing for Undetectable Minimal Residual Disease in Patients With Follicular Lymphoma
Patients with follicular lymphoma who have been treated and are in remission for at least 2 years may no longer be incurable based on highly sensitive testing. This may mean they no longer need therapy or active follow-up, according to findings presented by Sarraf Yazdy et al at the 2019 American...
Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study. Binghe Xu, MD, PhD, of the Department of ...
Elaine Fuchs, PhD, to Present Annual Block Lecture at The Ohio State University Comprehensive Cancer Center
Elaine Fuchs, PhD, is the recipient of the 24th annual Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer. It is given annually to a renowned cancer researcher who is invited to The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer...
ASH 2019: PET-Directed Therapy for Early-Stage DLBCL
Most people diagnosed with early-stage, or limited, diffuse large B-cell lymphoma (DLBCL) may be able to safely skip radiation treatment after a clear positron-emission tomography (PET) scan, according to new clinical trial results from SWOG presented by Persky et al at the 2019 American Society of ...
2019 Advanced Breast Cancer Award Goes to Fatima Cardoso, MD
The European School of Oncology (ESO), together with the Advanced Breast Cancer Global Alliance, bestowed the 2019 Advanced Breast Cancer Award upon Professor Fatima Cardoso, MD, Director of the Breast Unit of the Champalimaud Clinical Centre in Lisbon, “in recognition of her foresight in...
ASH 2019: Should African American Patients With AML and Evidence of Abnormal Kidney Function Be Enrolled Into Clinical Trials?
A study of more than 1,000 patients with acute myeloid leukemia (AML) revealed that African Americans were more likely to have evidence of abnormal kidney functioning than whites, but this was not associated with any difference in overall survival. The findings, presented by Statler et al at the...
Making Inroads With Interventional Oncology in the Treatment of Solid Tumors
At the recent 2019 Symposium on Clinical Interventional Oncology (CIO) in Miami, course directors Constantino Peña, MD, FSIR, and Ripal Gandhi, MD, FSIR, FSVM, had a lot to say about this burgeoning field of oncology. In particular, interventional oncology is making inroads in therapeutic...
FDA Approves Voxelotor for Sickle Cell Disease
On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to voxelotor (Oxbryta) for adults and pediatric patients 12 years of age and older with sickle cell disease. “[Voxelotor] is an inhibitor of deoxygenated sickle hemoglobin polymerization, which is the central...
ASH Recognized Choosing Wisely Champions at 2019 Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely® Champions, practitioners working to tackle the overuse of hematology tests and treatments, at its 2019 Annual Meeting & Exposition in Orlando: Stephen L. Wang, MD, of Kaiser Permanente Santa Clara Medical Center, Santa...
Databases: Where Math Meets Medicine
About 4 decades ago, as a young physician, I observed that most surgeons were numerator doctors; they remembered their successes and their failures, but they did not remember the frequency of either. There was no denominator. Worse, the approach to any specific surgical problem was always the...
ASH 2019: Genomic Features of AML in Patients Aged 60 or Older May Predict Stem Cell Transplant Outcome
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of leukemic genetic characteristics, according to results presented by Murdock et al at the 2019 American Society of Hematology (ASH) Annual...
Edward A. Stadtmauer, MD, on Advanced Multiple Myeloma and Sarcoma: First-in-Human Assessment of CRISPR-Edited T Cells
Edward A. Stadtmauer, MD, of the University of Pennsylvania Abramson Cancer Center, discusses phase I results of immune cells, modified with CRISPR/Cas9 technology, and infused in three patients (two with multiple myeloma and one with sarcoma). Researchers observed the cells expand and bind to...
Tait D. Shanafelt, MD, on CLL in Younger Patients: Comparing Ibrutinib and Rituximab With FCR
Tait D. Shanafelt, MD, of Stanford University, discusses extended follow-up data that show ibrutinib plus rituximab improved clinical outcomes vs the standard therapy of fludarabine/cyclophosphamide/ rituximab in younger patients with previously untreated chronic lymphocytic leukemia (Abstract 33).
Mhairi Copland, PhD, MB BChir, on Blast Phase CML: A Possible Treatment Advance
Mhairi Copland, PhD, MB BChir, of the University of Glasgow, discusses results of a study on the combination of ponatinib and fludarabine, cytarabine, idarubicin, and G-CSF for patients with blast phase chronic myeloid leukemia, a rare complication with a poor outcome (Abstract 497).
Nitin Jain, MD, on First-Line Ibrutinib Plus Venetoclax in CLL
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from two studies showing that the combination of ibrutinib and venetoclax is an effective chemotherapy-free oral regimen for patients with high-risk, previously untreated chronic lymphocytic leukemia (Abstract...
